Photos and videos
How many companies on AIM smash out a £15 million contract? Only #ORPH, horribly undervalued.
1 Jun 2022
We have signed a £14.7M contract with a top 5 global #pharma client which follows a recent #influenza #virus manufacturing contract. @hVIVO_UK will conduct a characterisation study and a follow on human challenge trial.
londonstockexchange.com/news…
#ORPH #challengestudy #hVIVO
1
1
2
We have the team already #ORPH
22 May 2022
Movies like Outbreak nailed it when they imagined a global disease-fighting team who is ready to respond to a crisis on a moment’s notice. Now we need to make it a reality. b-gat.es/3wF2U2I
Sogamla retweeted
18 Feb 2022
It's been almost a year since I called the top of the market❕
Is it time to return, given the narrative, expectation and outlook is so bad, yet reality will be so different...
Retweet - Yes Return ✅
Like - Stay in exile ❌
64
182
86
#orph expanding the number of challenge studies it can offer.
- At least £50m revenues in 2022 with considerable upside
- Expanding challenge study portfolio
- Profitable
- Three more spin outs two of which are possible blockbusters
- Cash dividend
What am I missing here.
3
1
3
Looking forward to hearing the #gfin TU. By the sounds of it business is going well.
18 Jan 2022
Since joining #GfinityDigitalMedia in Dec 2020 EpicStream.com has implemented a stringent SEO strategy, resulting in:
💥 900% growth in SEO traffic over 12 months
📈 Translating to growth from 160k monthly users to 1.6m
🙌 Boosting total MAUs to more than 3.4m
1
3
95% of the forecasted revenues for 2022 already contracted. £50 million will be surpassed with ease #ORPH
We have signed another £5m #influenza #humanchallenge study contract with a #biotech company developing an #antiviral drug for protection against #respiratory viral infections.
We have now signed 95% of our 2022 forecasted contracts.
otp.tools.investis.com/clien…
#ORPH #hVIVO
1
7
It’s been very tough with #ORPH since April. Still consider it significantly undervalued. Will come good but it’s a hard watch.
65% of 2022 revenues are already signed. Madness in the market when crap companies which make significant losses are valued higher in the same space.
3
6
Sogamla retweeted
15 Nov 2021
I see @finnCap reiterate their target price for #ORPH at 4️⃣4️⃣p after today’s excellent news for @OpenOrphan
…you can buy at half that price this morning! 👀
1
10
26
Definitely worth a listen #ORPH
25 Aug 2021
Our #ORPH Executive Chairman Cathal Friel joined @proactive_UK after announcing our @hVIVO arm has won an £8.1m contract with an unnamed ‘major global pharmaceutical company’ to test an antiviral product using its asthma human challenge study model…
proactiveinvestors.co.uk/com…
2
Love this interview with Cathal Friel the Executive Chairman of #ORPH. Lots and lots of news flow expected over the coming weeks and months.
My prediction by end of sept:
- News on covid challenge studies
- News on two spin outs
- More contract wins
🔥 🔥
24 Aug 2021
Here, our #ORPH Executive Chairman Cathal Friel catches up with @brr_mediauk to expand further on our £8.1m Asthma Human Challenge Study Contract Win…
brrmedia.co.uk/broadcasts-em…
1
2
A great contract win. This contract alone is worth more in revenue than a lot of pharma companies on AIM make in a year, and they have a higher market cap. What a strange market.
This is the start of the re-rate. Lots of news flow expected until year end. #Orph
24 Aug 2021
We are pleased to announce that @hVIVO_UK has signed an £8.1m contract with a major global pharma company to test its inhaled hRV antiviral using the #Asthma Human Challenge Study Model, adding to #ORPH’s exciting pipeline of challenge study contracts…
londonstockexchange.com/news…
1
4